RG2 [D74]细胞
ATCC Number： CRL-2433™
相关**： 其他**
生长状态： 贴壁生长
细胞形态： 其他
运输方式： 冻存运输
年限： fetus, 20 days gestation
器官来源： 大脑
是否是肿瘤细胞： 0
物种来源： 褐鼠
数量： 大量
Designations: RG2 [D74]
Depositors: RF Barth
RG2 [D74]细胞Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Rattus norvegicus deposited as rat
Morphology: glial
Source: Organ: brain
Disease: differentiated malignant glioma
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic: Yes
Age: fetus, 20 days gestation
Comments: This tumor was produced by Drs. A. Koestner and W. Wechsler at The Ohio State University in 1971.
A pregnant CD Fischer rat on day 20 of gestation was inoculated with a single dose of N-ethyl-N-nitrosourea (ENU) (50 mg/kg b.w.). Tumors were harvested and cloned. RG2 [D74]细胞[38592]
This cell line has been designated RG2 or RG-2 (rat glioma 2) and it is the same as that called D74-RG2 or D74.
This cell line may be used for both in vitro and in vivo studies of a rat brain tumor. It grows well in cell culture and provides a simple, reproducible glioma model when inoculated into the brains of syngeneic rats. [39807]
The biological characteristics of this tumor closely resemble those of human glioblastoma.
The transplantable tumor displays an infiltrative pattern of growth within the brain. [39813]
The RG2 cells are non-immunogenic in syngeneic Fischer rats despite intensive immunization. [38613]
The RG2 and F98 (ATCC CRL-2397) gliomas can be used as rat brain tumor models in experimental neuro-oncology. [39801]
RG2 was submitted to the American Type Culture Collection in March, 1999 at passage 3 from a culture established from a tumor.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:8 is recommended
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. RG2 [D74]细胞Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
Preservation: Culture medium, 95%; DMSO, 5%
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 38592: Ko L, et al. Morphological characterization of nitrosourea-induced glioma cell lines and clones. Acta Neuropathol. 51: 23-31, 1980. PubMed: 7435138
38606: Tzeng JJ, et al. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2. Cancer Res. 50: 4338-4343, 1990. PubMed: 2364388
38613: Tzeng JJ, et al. Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Res. 51: 2373-2378, 1991. PubMed: 2015600
39800: Kobayashi N, et al. An improved rat brain-tumor model. J. Neurosurg. 53: 808-815, 1980. PubMed: 7003068
39801: Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J. Neuro-Oncol. 36: 91-102, 1998. PubMed: 9525831
39803: Swenberg JA, et al. The induction of tumors of the nervous system with intravenous methylnitrosourea. Lab. Invest. 26: 74-85, 1972. PubMed: 4333080
39804: Swenberg JA, et al. RG2 [D74]细胞Quantitative aspects of transplacental tumor induction with ethylnitrosourea in rats. Cancer Res. 32: 2656-2660, 1972. PubMed: 4345400
39807: Aas AT, et al. The RG2 rat glioma model. J. Neuro-Oncol. 23: 175-183, 1995. PubMed: 7673979
39808: Groothuis DR, et al. Permeability of different experimental brain tumor models to horseradish peroxidase. J. Neuropathol. Exp. Neurol. 41: 164-185, 1982. PubMed: 7062086
39809: Groothuis DR, et al. Regional measurements of blood-to-tissue transport in experimental RG-2 rat gliomas. Cancer Res. 43: 3368-3373, 1983. PubMed: 6850641
39811: Rapoport SI. Osmotic opening of the blood-brain barrier. Ann. Neurol. 24: 677-684, 1988. PubMed: 3059990
39812: Ernestus RI, et al. Polyamine metabolism in experimental brain tumors of rat. J. Neurochem. 60: 417-422, 1993. PubMed: 8419528
39813: Ceberg CP, et al. A comparative study on the pharmacokinetics and biodistribution of boronated porphyrin (BOPP) and sulfhydryl boron hydride (BSH) in the RG2 rat glioma model. J. Neurosurg. 83: 86-92, 1995. PubMed: 7782856
39814: Ceberg CP, et al. Enhanced boron uptake in RG 2 rat gliomas by electropermeabilization in vivo--a new possibility in boron neutron capture therapy. Anticancer Drugs 5: 463-466, 1994. PubMed: 7949252
39833: Molnar P, et al. The effects of dexamethasone on experimental brain tumors: I. Transcapillary transport and blood flow in RG-2 rat gliomas. J. Neuro-Oncol. 25: 19-28, 1995. PubMed: 8523086
39835: Devineni D, et al. RG2 [D74]细胞Tissue distribution of methotrexate following administration as a solution and as a magnetic microsphere conjugate in rats bearing brain tumors. J. Neuro-Oncol. 24: 143-152, 1995. PubMed: 7562001
39836: Devineni D, et al. In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. Cancer Chemother Pharmacol. 38: 499-507, 1996. PubMed: 8823490
39837: Gallo JM, et al. Targeting anticancer drugs to the brain: II. Physiological pharmacokinetic model of oxantrazole following intraarterial administration to rat glioma-2 (RG-2) bearing rats. J. Pharmacokinet. Biopharm. 21: 575-592, 1993. PubMed: 8145132
39839: Tjuvajev J, et al. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res. 55: 1902-1910, 1995. PubMed: 7728757
